KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short term Debt: 2017-2025

Historic Short term Debt for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $7.2 million.

  • Amneal Pharmaceuticals' Short term Debt fell 96.79% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 96.79%. This contributed to the annual value of $224.2 million for FY2024, which is 25.26% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Short term Debt of $7.2 million as of Q3 2025, which was down 97.52% from $290.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Short term Debt registered a high of $290.0 million during Q1 2025, and its lowest value of $7.2 million during Q3 2025.
  • Over the past 3 years, Amneal Pharmaceuticals' median Short term Debt value was $179.0 million (recorded in 2024), while the average stood at $174.1 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Short term Debt soared by 227.62% in 2023, and later crashed by 96.79% in 2025.
  • Amneal Pharmaceuticals' Short term Debt (Quarterly) stood at $47.9 million in 2021, then rose by 25.36% to $60.0 million in 2022, then surged by 198.33% to $179.0 million in 2023, then rose by 25.26% to $224.2 million in 2024, then slumped by 96.79% to $7.2 million in 2025.
  • Its Short term Debt was $7.2 million in Q3 2025, compared to $290.0 million in Q2 2025 and $290.0 million in Q1 2025.